FOX04-DR 10mg

Posted by author-avatar
Once-daily subcutaneous protocol for senolytic peptide research.

FOX04-DR 10mg

FOXO4-DRI (also known as Proxofim) is a synthetic D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 protein interaction

Vial Size
Dose Range
Schedule
Primary Goal
10mg vial 250 to 500 mcg daily; starting low and titrating upward over time. Daily subcutaneous injections for 8 to 16 weeks with gradual dose escalation. Selectively clear senescent cells via disruption of FOXO4-p53 binding.

Reconstitution Summary

1 mL per 10 mg vial (10 mg/mL).

Storage Summary

Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw.
FOX04-DR 10mg
Recommended Product

FOX04-DR 10mg

View Product

Reconstitution Steps

  1. Draw 1 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl until dissolved (do not shake).
  4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

How It Works

FOXO4-DRI is a synthetic peptide that selectively targets senescent cells by blocking the FOXO4-p53 protein interaction. In normal cells, FOXO4 binds to p53 and sequesters it in the nucleus. In senescent cells, disrupting this interaction causes p53 to translocate to the mitochondria, triggering apoptotic cell death specifically in aged, dysfunctional cells while sparing healthy ones. Animal studies have demonstrated that FOXO4-DRI can reduce senescent cell burden, improve tissue function, and mitigate age-related pathologies. The peptide’s D-retro-inverso configuration enhances its stability and resistance to proteolytic degradation.

Benefits & Side Effects

  • Promotes selective clearance of senescent cells in various tissues, including aged organs and
    pathological conditions.
  • Animal studies show improvements in tissue regeneration, reduced inflammation, and enhanced organ
    function following senescent cell clearance.
  • In aged mice, FOXO4-DRI treatment improved testosterone levels and markers of cellular health.
    No human clinical safety or efficacy data currently exist; tolerability in humans remains uncharacterized.
  • Injection-site reactions (mild redness, irritation) may occur with subcutaneous administration.

References & Scientific Literature

  1. Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis (Nature Cell): original FOXO4-DRI discovery.
  2. FOXO4-DRI induces keloid senescent fibroblast apoptosis (Nature Communications Biology).
  3. FOXO4-DRI alleviates age-related testosterone secretion insufficiency (Aging, Albany NY).
  4. FOXO4 peptide ameliorates bleomycin-induced pulmonary fibrosis in mice (J Cellular and Molecular Medicine).
Older Ovagen 20mg